Sep 27

CT 01 - Clinical Trials Session

9 - 6-Year Overall Survival of Nivolumab Following Stereotactic Ablative Radiotherapy In Early-Stage Non-Small Cell Lung Cancer: Randomized I-SABR Trial

02:00pm - 02:10pm ET

Grand Ballroom

Presenter(s)

Joe Chang, MD, PhD, MS, FASTRO - MD Anderson Cancer Center, Houston, TX